Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q4 FY24
Glenmark's Q4 FY24 consolidated revenue grew 2.1% YoY to INR 3,063 crore, with India formulation up 12.9% and ROW up 10%, but North America declined 12.4% due to lack of launches.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q4 FY24 consolidated revenue grew 2.1% YoY to INR 3,063 crore, with India formulation up 12.9% and ROW up 10%, but North America declined 12.4% due to lack of launches. The company took significant exceptional charges (INR 447 crore loss) including Monroe asset impairment and working capital rationalization. Management guided FY25 revenue of INR 135-140 billion, EBITDA margin near 19%, and double-digit PAT margins. Key growth drivers include Rialtris (expected >$80M sales in FY25), generic Flovent filing, and Europe/emerging markets expansion. Risks include delayed Monroe FDA reinspection, elevated legal payouts (~INR 300 crore cash outflow in FY25), and IGI R&D spend of $50 million.
ग्लेनमार्क की चौथी तिमाही में कुल कमाई 2.1% बढ़कर 3,063 करोड़ रुपये हुई। भारत में दवाओं की बिक्री 12.9% और बाकी देशों में 10% बढ़ी, लेकिन उत्तर अमेरिका में नई दवाओं की कमी से 12.4% गिरावट आई। कंपनी ने 447 करोड़ रुपये का एकमुश्त घाटा दिखाया, जिसमें मुनरो कारखाने की घटी हुई कीमत और कार्यशील पूंजी में सुधार शामिल है। अगले साल कमाई 13,500-14,000 करोड़ रुपये रहने का अनुमान है, जिसमें मुनाफा 19% और शुद्ध मुनाफा 10% से अधिक रहेगा। मुख्य चीजें हैं: रियाल्ट्रिस दवा (80 करोड़ डॉलर से अधिक बिक्री), फ्लोवेंट जेनेरिक दाखिल करना, और यूरोप-उभरते बाजारों में विस्तार। जोखिम हैं: मुनरो कारखाने की FDA जांच में देरी, 300 करोड़ रुपये का कानूनी भुगतान, और IGI रिसर्च पर 50 करोड़ डॉलर खर्च।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Monroe facility FDA reinspection delay
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Formulation Growth (Q4)
12.9%
+12.9% YoY
India formulation sales grew to INR 9,391 million, outperforming IPM growth of 5.6%.
North America Revenue (Q4)
$91M
-12.4% YoY
North America revenue declined due to lack of meaningful product launches and scale-up delays.
Rialtris FY25 Sales Target
$80M+
~100% YoY
Rialtris sales expected to double in FY25, driven by new market launches and US partner Hikma.
Net Cash Position
INR 667.7 crore
down from INR 3,300 crore H1
Net cash declined sharply after GLS divestment proceeds were offset by legal settlements and working capital adjustments.
What Changed vs Last Quarter
NEW
FY25 consolidated revenue target INR 135,000-140,000 million
Management guided FY25 revenue between INR 135-140 billion, implying ~14-18% growth over FY24.
NEW
FY25 EBITDA margin target close to 19%
EBITDA margin expected to be near 19% for full year FY25, supported by mix improvement and cost control.
NEW
FY25 R&D investment 7%-7.25% of revenue
R&D spend guided at 7-7.25% of total revenue, with generic R&D increasing and IGI spend declining.
NEW
FY25 consolidated capital investment INR 7,000 million
CapEx of INR 700 crore planned for additional lines, Rialtris capacity, and in-licensing opportunities.
DROPPED
India business to return to ~INR 1,000 crore quarterly run rate in Q4
After the one-time restructuring, India primary sales will normalize to ~INR 1,000 crore per quarter, growing 10-12% YoY.
DROPPED
Ryaltris FY25 sales of ~$80 million
Management expects Ryaltris to generate ~$80 million in booked sales in FY25, with high margins.
DROPPED
R&D spend to reduce by $30-35 million in FY25
IGI alliance will lower annual R&D spend from $75-80 million to $45-50 million, boosting EBITDA.
DROPPED
Net cash positive by end of FY24
Proceeds from GLS divestment (~INR 5,000 crore net) will make the company net cash positive by March 2024.
NEW RISK
Monroe facility FDA reinspection delay
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
NEW RISK
Elevated legal settlement cash outflows
Cash payout of ~INR 300 crore in FY25 for DOJ and Zetia settlements, impacting free cash flow.
NEW RISK
North America revenue decline and lack of launches
North America revenue fell 12.4% YoY; recovery depends on generic Flovent approval and scale-up of recent launches.
NEW RISK
IGI R&D spend remains high at $50 million
Despite earlier guidance to reduce Ichnos spend, FY25 IGI cash R&D is $50 million, pressuring profitability.
RISK GONE
Monroe facility ramp-up delays
Monroe plant is awaiting FDA inspection; any delay in approval or commercialization could impact injectable revenue and margin improvement.
RISK GONE
U.S. respiratory launch timeline uncertainty
Generic Flovent pMDI NDA filing expected in Q1 FY25, but approval and launch timing remain uncertain, affecting U.S. growth trajectory.
RISK GONE
India business recovery may be slower than guided
Despite guidance of INR 1,000 crore quarterly run rate, the one-time restructuring impact may have lingering effects on channel dynamics.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Europe business expected to grow at a minimum of 15-20% going forward, driven by respiratory portfolio and Ryaltris.
Mentioned in Q1 FY24, Q2 FY24
India business growth was impacted by slowdown in respiratory and dermatology; while October showed recovery, sustainability is uncertain.
Fast read
Guidance and risk preview
Management guided FY25 revenue between INR 135-140 billion, implying ~14-18% growth over FY24.
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
View Risks →